{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:45:19Z","timestamp":1792176319986,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bioorg.2019.103522","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T05:22:54Z","timestamp":1576646574000},"page":"103522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines"],"prefix":"10.1016","volume":"95","author":[{"given":"Kalpana","family":"Tilekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"J\u00e4nsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schweipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Mrowka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"Meyer-Almes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Ramaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2019.103522_b0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2019.103522_b0010","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-Cell Lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2019.103522_b0015","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2019.103522_b0020","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1517\/14728220903241658","article-title":"Targeting of HDAC8 and investigational inhibitors in neuroblastoma","volume":"18","author":"Oehme","year":"2009","journal-title":"Exp. Opin. Invest. Drugs"},{"key":"10.1016\/j.bioorg.2019.103522_b0025","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2008.9","article-title":"A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas","volume":"22","author":"Balasubramanian","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2019.103522_b0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2015.04.013","article-title":"HDAC8: a multifaceted target for therapeutic interventions","volume":"36","author":"Chakrabarti","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2019.103522_b0035","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4155\/fmc-2016-0117","article-title":"Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases","volume":"8","author":"Chakrabarti","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0040","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4155\/fmc-2017-0130","article-title":"Structure\u2013activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery","volume":"9","author":"Amin","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0045","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.phrs.2018.03.001","article-title":"Structure-activity relationships of HDAC8 inhibitors: non-hydroxamates as anticancer agents","volume":"131","author":"Amin","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2019.103522_b0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why hydroxamates may not be the best histone deacetylase inhibitors-what some may have forgotten or would rather forget?","volume":"11","author":"Shen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2019.103522_b0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bioorg.2019.103522_b0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2019.103522_b0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/med.20024","article-title":"Histone deacetylation in epigenetics: an attractive target for anticancer therapy","volume":"25","author":"Mai","year":"2005","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2019.103522_b0070","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0075","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1016\/j.bmc.2011.06.030","article-title":"Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors","volume":"19","author":"Whitehead","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0080","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/cmdc.200900309","article-title":"Azetidinones as zinc-binding groups to design selective HDAC8 Inhibitors","volume":"4","author":"Galletti","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2019.103522_b0085","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/carcin\/bgp147","article-title":"Keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells","volume":"30","author":"Nian","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2019.103522_b0090","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1124\/jpet.103.055541","article-title":"Identification of novel isoform-selective inhibitors within class I Histone Deacetylases","volume":"307","author":"Hu","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2019.103522_b0095","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/cmdc.201600528","article-title":"Potent and selective non-hydroxamate histone deacetylase 8 inhibitors","volume":"11","author":"Kleinschek","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2019.103522_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111756","article-title":"Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors","volume":"184","author":"Wolff","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0110","unstructured":"J.J. Buggy, B. Sriram, M.S. Susanne, inventors; Pharmacyclics Inc., assignee; 2015. Uses of selective inhibitors of HDAC8 and treatment of inflammatory conditions. US20150038542."},{"key":"10.1016\/j.bioorg.2019.103522_b0115","doi-asserted-by":"crossref","first-page":"9562","DOI":"10.1021\/jm300837y","article-title":"Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 Using click chemistry to generate candidate libraries","volume":"55","author":"Suzuki","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0120","unstructured":"Aaron Beaty Beeler, John A. Porco, Jr., Oscar J. Ingham, James E. Bradner, inventors; Trustees of Boston University, assignee; 2015. Selective histone deacetylase 8 inhibitors. US20150352079."},{"key":"10.1016\/j.bioorg.2019.103522_b0125","unstructured":"A. Oyelere, G. Berkley , inventors; 2013. Histone deacetylase (HDAC) inhibitors targeting prostate tumors and method of making and using thereof. US20130289085."},{"key":"10.1016\/j.bioorg.2019.103522_b0130","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/cmdc.201200300","article-title":"Synthesis and biological evaluation of ortho -aryl N -hydroxycinnamides as potent histone deacetylase (HDAC) 8 Isoform-Selective Inhibitors","volume":"7","author":"Huang","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2019.103522_b0135","unstructured":"W. Xu, Y. Zhang, W. Song, inventors; Shouguang Fukang Pharmaceuticals Ltd., assignee; 2012. Preparative method and use of ZYJ-D08A and its epimers as histone deacetylase inhibitors. WO2012174730."},{"key":"10.1016\/j.bioorg.2019.103522_b0140","unstructured":"W. Xu, Y. Zhang, H. Fang, inventors; Shandong University, assignee; 2010. Tyrosine derivatives as histone deacetylase inhibitors and using thereof. CN101723896."},{"key":"10.1016\/j.bioorg.2019.103522_b0145","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bmc.2010.01.060","article-title":"Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors","volume":"18","author":"Zhang","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0150","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1021\/jm101605z","article-title":"Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities","volume":"54","author":"Zhang","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0155","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1016\/j.bmcl.2007.02.064","article-title":"Design and evaluation of \u2018Linkerless\u2019 hydroxamic acids as selective HDAC8 inhibitors","volume":"17","author":"KrennHrubec","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.103522_b0160","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/13543776.2017.1276565","article-title":"Selective histone deacetylase small molecule inhibitors: recent progress and perspectives","volume":"27","author":"Qin","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2019.103522_b0165","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1016\/j.bmcl.2010.03.092","article-title":"Benzimidazole and imidazole inhibitors of histone deacetylases: synthesis and biological activity","volume":"20","author":"Bressi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.103522_b0170","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s00044-011-9623-3","article-title":"Design, synthesis, and biological evaluation of novel 2,4-thiazolidinedione derivatives as histone deacetylase inhibitors targeting liver cancer cell line","volume":"21","author":"Mohan","year":"2012","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2019.103522_b0175","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1021\/acs.jmedchem.8b01087","article-title":"Characterization of Histone Deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants","volume":"61","author":"Marek","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0180","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/ci500762z","article-title":"Enhancing the sensitivity of pharmacophore-based virtual screening by incorporating customized ZBG features: a case study using histone deacetylase 8","volume":"55","author":"Hou","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2019.103522_b0185","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1016\/j.ejmech.2010.07.014","article-title":"Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives","volume":"45","author":"Patil","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0190","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2174\/1871520618666180423111309","article-title":"Novel anthraquinone derivatives as dual inhibitors of topoisomerase 2 and casein kinase 2. In silico studies, synthesis and biological evaluation on leukemic cell lines","volume":"18","author":"Kabir","year":"2019","journal-title":"ACAMC"},{"key":"10.1016\/j.bioorg.2019.103522_b0195","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1248\/cpb.39.1440","article-title":"Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds","volume":"39","author":"Momose","year":"1991","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2019.103522_b0200","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.0813345106","article-title":"Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression","volume":"106","author":"Auld","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2019.103522_b0205","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nbt0310-185","article-title":"GSK\/Sirtris compounds dogged by assay artifacts","volume":"28","author":"Schmidt","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioorg.2019.103522_b0210","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nbt0511-373","article-title":"PARP inhibitors stumble in breast cancer","volume":"29","author":"Guha","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioorg.2019.103522_b0215","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/1078-0432.CCR-11-1973","article-title":"Iniparib Nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP Inhibitor","volume":"18","author":"Liu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2019.103522_b0220","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.conb.2016.11.004","article-title":"Human-specific genomic signatures of neocortical expansion","volume":"42","author":"Florio","year":"2017","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.bioorg.2019.103522_b0225","doi-asserted-by":"crossref","unstructured":"M. Florio, M. Heide, A. Pinson, H. Brandl, M. Albert, S. Winkler, P. Wimberger, W.B. Huttner, M. Hiller, Evolution and cell-type specificity of human-specific genes preferentially expressed in progenitors of fetal neocortex. eLife, 7 (2018) e32332. 10.7554\/eLife.32332.","DOI":"10.7554\/eLife.32332"},{"key":"10.1016\/j.bioorg.2019.103522_b0230","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3892\/ijo.2015.3182","article-title":"The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma","volume":"47","author":"Song","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2019.103522_b0235","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1007\/s10620-013-2867-7","article-title":"The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma","volume":"58","author":"Wu","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bioorg.2019.103522_b0240","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1021\/jm7011408","article-title":"Histone deacetylase inhibitors: from bench to clinic","volume":"51","author":"Paris","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0245","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23070","article-title":"HDAC inhibitor PAC-320 induces G2\/M cell cycle arrest and apoptosis in human prostate cancer","volume":"9","author":"Dong","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2019.103522_b0250","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0404603101","article-title":"Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor","volume":"101","author":"Vannini","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2019.103522_b0255","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1021\/acs.biochem.5b00010","article-title":"Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8","volume":"54","author":"Decroos","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2019.103522_b0260","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.str.2004.04.012","article-title":"Structural snapshots of human HDAC8 Provide Insights into the Class I histone deacetylases","volume":"12","author":"Somoza","year":"2004","journal-title":"Structure"},{"key":"10.1016\/j.bioorg.2019.103522_b0265","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.drudis.2015.01.004","article-title":"How the flexibility of human histone deacetylases influences ligand binding: an overview","volume":"20","author":"Deschamps","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2019.103522_b0270","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2019.103522_b0275","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.redox.2018.09.013","article-title":"The enzyme activity of histone deacetylase 8 is modulated by a redox-switch","volume":"20","author":"J\u00e4nsch","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.bioorg.2019.103522_b0280","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2307\/2530598","article-title":"Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models","volume":"34","author":"Volund","year":"1978","journal-title":"Biometrics"},{"key":"10.1016\/j.bioorg.2019.103522_b0285","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1515\/hsz-2018-0363","article-title":"Kinetically selective and potent inhibitors of HDAC8","volume":"400","author":"Schweipert","year":"2019","journal-title":"Biol. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0290","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1107\/S2053229617018551","article-title":"Synthesis, crystal structure and biological properties of a cis -dichloridobis(diimine)copper(II) complex","volume":"74","author":"Bhat","year":"2018","journal-title":"Acta Crystallogr. C Struct. Chem."},{"key":"10.1016\/j.bioorg.2019.103522_b0295","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/08982104.2018.1556292","article-title":"Factorial design based curcumin ethosomal nanocarriers for the skin cancer delivery: in vitro evaluation","volume":"29","author":"Peram","year":"2019","journal-title":"J. Liposome Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819316335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819316335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:56:15Z","timestamp":1758614175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206819316335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":58,"alternative-id":["S0045206819316335"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.103522","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.103522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103522"}}